Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Generic formats like JSON or XML are easier to version than forms. However, they were not originally intended to be human-readable but machine-readable. Since many applications require a ...

The Paralegal Certificate Program is designed and taught by local, practicing attorneys to prepare participants to be knowledgeable, ethical, and effective while emphasizing legal areas where ...

The World Bank’s Development Economics Vice Presidency (DEC) provides scholarships to students and young researchers, contributing to the World Bank’s mission of forging new dynamic approaches to ...

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She’s a certified sleep science coach and ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...